References - Penlac® Nail Lacquer
FOR U.S. RESIDENTS ONLY
Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8%: Safe and on target
About Nail Fungus Treatment with Penlac® For People with Diabetes For Healthcare Professionals
Search













References

  1. Penlac® Prescribing Information, Dermik Laboratories; 2006.

  2. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70-S80.

  3. Data on file, Dermik Laboratories.

  4. Bohn M, Kraemer K. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc. 2000;90:491-494.

  5. Gupta AK, Plott T. Ciclopirox: a broadspectrum antifungal with antibacterial and anti-inflammatory properties. Int J Dermatol. 2004;43(suppl 1):3-8.

  6. Kokjohn K, Bradley M, Griffiths B, Ghannoum M. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol. 2003;42(suppl 1):11-17.

  7. Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs. 1985;29:330-341.

  8. Hänel H, Raether W, Dittmar W. Evaluation of fungicidal action in vitro and in a skin model considering the influence of penetration kinetics of various standard antimycotics. Ann N Y Acad Sci. 1988;544:329-337.

  9. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139:665-671.

  10. Robbins JM. Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications. 2003;17:98-104.

  11. Boyko WL, Doyle JJ, Ryu S, Gause DO. Onychomycosis and its impact on secondary infection development in the diabetic population [abstract]. Value Health. 1999;2:199. Abstract PDD5.

  12. Doyle JJ, Boyko W, Ryu S, Gause D. Onychomycosis among diabetic patients: prevalence and impact of nonfungal foot infections [poster]. Diabetes. 2000;49(suppl 1):A195-A196. Poster 808-P.

Penlac® is indicated in immunocompetent patients with mild to moderate onychomycosis without lunula involvement due to Trichophyton rubrum.
IMPORTANT SAFETY INFORMATION
Penlac®, part of a comprehensive management program, includes regular removal of the unattached, infected nail by a health care professional, especially for patients with diabetes. Clinical data regarding use of systemic antifungals and Penlac® is not available to support concomitant use. Penlac® is well-tolerated: treatment-related side effects were periungual erythema (5%) and nail disorders (2%).

Patients with insulin-dependent diabetes or those with diabetic neuropathy were not included in pivotal clinical trials with Penlac®.
For more information, please see Full Prescribing Information for Penlac®

Your privacy
Dermik Laboratories respects your interest in keeping your personal health information private. The information you provide below will be used only for the purpose of sending an email message to the recipient and will not be saved. For more information, see our Privacy Policy.

Your name:

Your email address:

Recipient's email address:






Processing...





Thank you!
Your email has been sent.